A major 2026 trend in the primary hepatocyte market is the rise of "patient-derived" cells, allowing for highly personalized drug response studies. In 2026, pharmaceutical giants are increasingly sourcing hepatocytes from individuals with specific genetic backgrounds or liver pathologies to test how new medications interact with diverse populations. This 2026 precision medicine approach is...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
china 
thai
English
French
Spanish
Portuguese
Italiano
Romaian
Portuguese (Brazil)